Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Thermo Fisher Scientific undervalued by 24%, intrinsic value estimated at $597

EditorPollock Mondal
Published 11/09/2023, 07:12 AM
Updated 11/09/2023, 07:12 AM
© Reuters.

Thermo Fisher Scientific Inc. (NYSE:TMO) appears to be undervalued by approximately 24%, based on a two-stage growth model and discounted cash flow (DCF) model that estimates its intrinsic value at $597 per share, according to an analysis published Today. The current share price of the company stands at $454, indicating a significant gap between the market price and the estimated intrinsic value.

The financial models used in the analysis project ten-year cash flows, accounting for both growing and shrinking free cash flow situations. They consider an initial high growth phase and a later stable growth phase. This discrepancy between the current share price and the estimated intrinsic value is larger than the analyst price target of $529.

This assessment suggests there could be potential for investors in Thermo Fisher Scientific, given the disparity between its market price and estimated intrinsic value. However, it's important for investors to conduct their own due diligence as market conditions and company performance can change rapidly.

InvestingPro Insights

In addition to the potential undervaluation highlighted in the article, InvestingPro data and tips further underscore Thermo Fisher Scientific Inc.'s (NYSE:TMO) investment potential.

InvestingPro data shows that TMO's management has been proactively buying back shares, a move that often indicates confidence in the company's future performance. This is complemented by a strong earnings record that has allowed the company to continue dividend payments, even raising its dividend for 5 consecutive years. This is a clear sign of the company's commitment to returning value to its shareholders.

However, it's worth noting that there's been a declining trend in earnings per share, and 18 analysts have revised their earnings predictions downwards for the upcoming period. This suggests potential headwinds in the short-term, but the company's longstanding position as a prominent player in the Life Sciences Tools & Services industry, coupled with high returns on book equity, indicate a resilient business model.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

InvestingPro tips also highlight that TMO's stock generally trades with low price volatility, providing a degree of stability for investors. The company has also been profitable over the last twelve months, and analysts predict it will continue to be profitable this year.

These are just a few of the insights available on InvestingPro, which offers an extensive array of data and tips for numerous companies. For a deeper dive into TMO and other investment opportunities, consider exploring InvestingPro's comprehensive suite of resources.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.